🔗 Share this article The Global Health Body Issues Concern Over Acute Scarcity of Obesity Medications Fewer than one in 10 patients who could benefit from obesity jabs like Wegovy have access to them, warns the WHO as it releases its first guidance on the medications. Considering over a billion individuals worldwide now classified as obese, it is calling for broader and more equitable availability to this class of drugs. Per projections, more than two billion will be living with obesity by 2030 if no action is taken. "The new guidance recognises that obesity is a lifelong illness that can be treated with thorough and ongoing treatment," remarked the agency's head Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and distribution challenges are major hurdles to widespread access to the treatments that can aid individuals in losing significant body mass, says the body. Weight-Loss Drug Supply Crisis Despite the present best projected outlook, the supply of GLP-1 therapies could only cover approximately 100 million people – less than 10% of eligible patients, as stated by the WHO. The recommendation encourages nations and manufacturers to increase availability, through measures like patent sharing. Exclusive production rights on semaglutide – the primary component of a leading brand – is due to expire in several nations in 2026. How Weight-Loss Injections Work GLP-1 drugs replicate a biological compound to slow digestion, suppress the appetite and increase satiety so individuals reduce food intake. Individuals commonly begin shedding pounds within a few weeks of starting on the regular doses. Evidence points to patients may put most of the weight back on after a year of discontinuing the drug, as their typical appetite come back. To be above a healthy weight increases your likelihood for experiencing diseases, including diabetes, cardiovascular issues, stroke, and some malignancies. Obesity affects people in every country and was responsible for millions of deaths worldwide in 2024, as per the WHO.
Fewer than one in 10 patients who could benefit from obesity jabs like Wegovy have access to them, warns the WHO as it releases its first guidance on the medications. Considering over a billion individuals worldwide now classified as obese, it is calling for broader and more equitable availability to this class of drugs. Per projections, more than two billion will be living with obesity by 2030 if no action is taken. "The new guidance recognises that obesity is a lifelong illness that can be treated with thorough and ongoing treatment," remarked the agency's head Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and distribution challenges are major hurdles to widespread access to the treatments that can aid individuals in losing significant body mass, says the body. Weight-Loss Drug Supply Crisis Despite the present best projected outlook, the supply of GLP-1 therapies could only cover approximately 100 million people – less than 10% of eligible patients, as stated by the WHO. The recommendation encourages nations and manufacturers to increase availability, through measures like patent sharing. Exclusive production rights on semaglutide – the primary component of a leading brand – is due to expire in several nations in 2026. How Weight-Loss Injections Work GLP-1 drugs replicate a biological compound to slow digestion, suppress the appetite and increase satiety so individuals reduce food intake. Individuals commonly begin shedding pounds within a few weeks of starting on the regular doses. Evidence points to patients may put most of the weight back on after a year of discontinuing the drug, as their typical appetite come back. To be above a healthy weight increases your likelihood for experiencing diseases, including diabetes, cardiovascular issues, stroke, and some malignancies. Obesity affects people in every country and was responsible for millions of deaths worldwide in 2024, as per the WHO.